B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) [Phase 3]
Phase 3 clinical trial evaluating Sonrotoclax plus Zanubrutinib versus placebo plus Zanubrutinib in adults with relapsed/refractory mantle c…
-
CLINICAL_TRIALS trial_result · 2026-04-17Clinical Trial Update: Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers [Phase 2]
This clinical trial update summarizes long-term safety data for pirtobrutinib in participants with previously treated blood cancers from a P…
-
CLINICAL_TRIALS trial_result · 2026-04-16Clinical Trial Update: MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM) [Phase 1]
Phase 1 clinical trial update for MB-CART19.1 in CD19+ B-cell malignancies sponsored by Miltenyi Biomedicine GmbH. The study includes recurr…
-
CLINICAL_TRIALS trial_result · 2026-04-09Clinical Trial Update: Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma [Phase 2]
This document reports an ongoing Phase II trial assessing the combination of palbociclib and ibrutinib in mantle cell lymphoma, with the stu…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation [Phase 1]
This Phase 1 trial evaluated donor-derived anti-CD19 CAR-T cells in patients with recurrent or persistent B-cell malignancies after allogene…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-03Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies [Phase 1, Phase 2]
A completed Phase 1/2 study evaluating CTX131 in adults with relapsed or refractory hematologic malignancies, assessing safety and efficacy …
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) [Phase 1]
A Phase 1 study of LY4152199 in previously treated B-cell cancers is listed, with the trial currently NOT_YET_RECRUITING.
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma [Phase 1]
Phase 1 trial update reporting completion of a study evaluating CD19-targeted CAR T cells in relapsed or refractory CD19-positive B-cell lym…
-
CLINICAL_TRIALS trial_result · 2026-02-05Clinical Trial Update: Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003) [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating the safety and efficacy of combining favezelimab (MK-4280) with pembrolizumab (MK-3475) in patients wi…
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL [Phase 1, Phase 2]
A completed Phase 1/2 clinical trial of the oral BTK inhibitor LOXO-305 (pirtobrutinib) in patients with previously treated chronic lymphocy…
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: CD22 Redirected Autologous T Cells for ALL [Phase 1]
Phase 1 clinical trial update on autologous T cells redirected to CD22 for B-cell leukemias and lymphomas, sponsored by the University of Pe…
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) [NA]
Clinical trial update on adaptive bridging radiotherapy for relapsed/refractory B-cell lymphomas prior to CAR-T therapy; the study status is…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. [Phase 4]
This Phase 4 trial update describes extending ibrutinib treatment for patients who continue to benefit from the therapy.
-
CLINICAL_TRIALS trial_result · 2025-10-28Clinical Trial Update: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas [Phase 1]
A Phase 1 dose-finding study of ASP2802 in CD20-positive B-cell lymphomas was conducted, but the study has been terminated.
-
CLINICAL_TRIALS trial_result · 2025-10-24Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) [Phase 1, Phase 2]
This clinical trial update reports safety and efficacy data for CTX110 in relapsed or refractory B-cell malignancies, including Non-Hodgkin …
-
CLINICAL_TRIALS trial_result · 2025-10-09Clinical Trial Update: Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies [Phase 1]
Phase 1 trial update examining loncastuximab tesirine with DA-EPOCH-R for previously untreated aggressive B-cell lymphoid malignancies; the …
-
CLINICAL_TRIALS trial_result · 2025-10-01Clinical Trial Update: IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas [Phase 1]
Phase 1 study update for IKS03 in advanced B-cell non-Hodgkin lymphomas is currently recruiting across multiple subtypes including diffuse l…
-
CLINICAL_TRIALS trial_result · 2025-09-29Clinical Trial Update: BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors [EARLY_Phase 1]
A phase 1 clinical trial of BAFFR CAR-T therapy for relapsed/refractory B-cell tumors is not yet recruiting, sponsored by Guangzhou Bio-gene…
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) [Phase 1]
Phase I clinical trial update for BR101801 in adults with advanced hematologic malignancies; the study has completed.
-
CLINICAL_TRIALS trial_result · 2025-08-22Clinical Trial Update: FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101) [Phase 1]
Phase 1 FT522-101 study evaluating FT522 in combination with Rituximab for relapsed/refractory B-cell lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2025-08-21Clinical Trial Update: INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112) [Phase 1]
Phase 1 trial CITADEL-112 evaluating INCB050465 in combination with Rituximab, Bendamustine with Rituximab, or Ibrutinib in previously treat…
-
CLINICAL_TRIALS trial_result · 2025-08-11Clinical Trial Update: ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies [Phase 1]
Acepodia Biotech's Phase 1 trial of ACE1831 in adults with relapsed/refractory CD20-expressing B-cell malignancies is currently recruiting a…
-
CLINICAL_TRIALS trial_result · 2025-08-03Clinical Trial Update: Occurrence of Acute Kidney Injury After CAR-T Cells Treatments in B-cell Lymphoma.
An ongoing clinical trial update notes occurrences of acute kidney injury after CD19-directed CAR-T cell therapy in patients with B-cell lym…
-
CLINICAL_TRIALS trial_result · 2025-07-30Clinical Trial Update: Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma [Phase 2]
Phase 2 study of a dual CD22/CD19 CAR-T therapy as first-line consolidation for B-cell lymphoma, with the trial currently active but not rec…
-
CLINICAL_TRIALS trial_result · 2025-07-17Clinical Trial Update: Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies [Phase 2]
Phase 2 clinical trial update evaluating a bridging regimen containing mitoxantrone hydrochloride liposome injection together with CD19-targ…